{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [3, 5], "question": "How did the adjusted EBITDA change from 2022 to 2023 for both the Degree Program Segment and the Alternative Credential Segment?", "prediction": "Adjusted EBITDA for the Degree Program Segment increased from $180.7 million in 2022 to $214.7 million in 2023, representing a 19% increase. Meanwhile, adjusted EBITDA for the Alternative Credential Segment remained negative, increasing from negative $55.6 million in 2022 to negative $43.9 million in 2023, representing a 21% decrease in the magnitude of the loss.", "ground_truth": "The adjusted EBITDA for the Degree Program Segment increased by $34 million from $180.7 million in 2022 to $214.7 million in 2023, while the Alternative Credential Segment's negative adjusted EBITDA improved by $11.7 million from -$55.6 million in 2022 to -$43.9 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [1, 4], "question": "How did the level of impairment charges for goodwill change in the Degree Program Segment and Alternative Credential Segment from 2022 to 2023?", "prediction": "The level of impairment charges for goodwill decreased in the Alternative Credential Segment from $78,991 million in 2022 to $79,471 million (including $62.8 million in the fourth quarter of 2023) in 2023, but remained the same in the Degree Program Segment at $0 for both years.", "ground_truth": "In the Degree Program Segment, there were no impairment charges for goodwill in either 2022 or 2023, whereas in the Alternative Credential Segment, goodwill impairment charges increased from $78.991 million in 2022 to $79.471 million in 2023."}
{"type": "financial", "level": "comp", "file": "2U, Inc..txt", "comp_parts": [0, 3], "question": "How did Full Course Equivalent (FCE) enrollments change in both the Degree Program Segment and the Alternative Credential Segment from 2022 to 2023?", "prediction": "In the Degree Program Segment, FCE enrollments decreased by 39,061, from 233,635 in 2022 to 194,574 in 2023. In the Alternative Credential Segment, FCE enrollments decreased by 4,088, from 93,471 in 2022 to 89,383 in 2023.", "ground_truth": "FCE enrollments decreased by 16.7% in the Degree Program Segment from 233,635 in 2022 to 194,574 in 2023, while they increased by 4.5% in the Alternative Credential Segment from 93,471 in 2022 to 97,647 in 2023."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 2], "question": "What were the main factors contributing to the decline in gross profit for 3D Systems Corporation in the year ended December 31, 2022, as compared to 2021?", "prediction": "The main factors contributing to the decline in gross profit were divestitures, cost inflation, and supply chain pressures.", "ground_truth": "The decline in gross profit for 3D Systems Corporation in 2022 compared to 2021 was primarily due to divestitures, lower sales volumes in the dental market, and inflationary cost pressures, as indicated by the financial data provided."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [2, 5], "question": "How did the impairment charges on property and equipment and the amortization expense related to intangible assets change from 2021 to 2022?", "prediction": "Impairment charges on property and equipment decreased from $788 in 2021 to $18 in 2022. Amortization expense related to intangible assets increased from $10,469 in 2021 to $15,480 in 2022.", "ground_truth": "The impairment charges decreased from $788,000 in 2021 to $18,000 in 2022, while amortization expense increased from $10,469,000 in 2021 to $15,480,000 in 2022."}
{"type": "financial", "level": "comp", "file": "3D Systems Corp..txt", "comp_parts": [0, 1], "question": "How did the operating income for Healthcare Solutions and Industrial Solutions segments change from 2021 to 2022?", "prediction": "According to the provided text, the operating income for Healthcare Solutions decreased from $69.4 million in 2021 to $25.8 million in 2022, and the operating income for Industrial Solutions decreased from $48.6 million in 2021 to $22.8 million in 2022.", "ground_truth": "The operating income for Healthcare Solutions decreased by $43.5 million from $69.4 million in 2021 to $25.9 million in 2022, while for Industrial Solutions it decreased by $25.7 million from $48.6 million in 2021 to $22.8 million in 2022."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [2, 4], "question": "How much interest income did Block, Inc. earn from customer funds in 2023, and how did it compare to the previous years?", "prediction": "Block, Inc. earned $153.5 million in interest income from customer funds in 2023. This is the first time Block, Inc. has reported interest income from customer funds, as it was immaterial in the previous years.", "ground_truth": "In 2023, Block, Inc. earned $153.5 million in interest income from customer funds, which was immaterial in both 2022 and 2021."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 2], "question": "How did the organizational structure change with respect to Block, Inc's management reporting in the fourth quarter of 2023 affect the allocation of BNPL platform financial results?", "prediction": "In the fourth quarter of 2023, Block, Inc. reorganized its business structure and moved the financial results of its BNPL platform fully under the Cash App segment, rather than allocating 50% of revenue and gross profit from the BNPL platform to each of the Square and Cash App segments.", "ground_truth": "In the fourth quarter of 2023, Block, Inc. changed its management reporting structure, moving the business activities and management of its BNPL platform fully under the Cash App segment, thus ceasing the previous practice of allocating 50% of revenue and gross profit from the BNPL platform to both the Square and Cash App segments."}
{"type": "financial", "level": "comp", "file": "Block, Inc..txt", "comp_parts": [0, 4], "question": "How did the classification of consumer receivables and their allowance for credit losses change from January 31, 2022 to December 31, 2023?", "prediction": "From January 31, 2022 to December 31, 2023, the classification of consumer receivables and their allowance for credit losses shifted from being considered as loans held for sale to being classified as loans held for investment, as part of the normal course of business and as per accounting standards, specifically ASU 2016-13.", "ground_truth": "The consumer receivables classified as 'Pass' increased to $2.5 billion with $185.275 million in credit loss allowance by December 31, 2023, from the time of Afterpay's acquisition in January 2022 where the beginning allowance was $115.552 million."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [4, 5], "question": "What was the percentage change in the net property and equipment values for C.H. Robinson Worldwide, Inc. between December 31, 2022, and December 31, 2023?", "prediction": "The net property and equipment value decreased by 9.3% from $159,432 (thousands) in 2022 to $144,718 (thousands) in 2023.", "ground_truth": "The net property and equipment values decreased by approximately 9.2% from $159,432,000 on December 31, 2022, to $144,718,000 on December 31, 2023."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [1, 3], "question": "What were the primary factors affecting C.H. Robinson's financial performance in 2023 as indicated in the financial statements?", "prediction": "The primary factors affecting C.H. Robinson's financial performance in 2023 included weak freight demand, excess carrier capacity, and declining transportation rates, which resulted in decreased total revenues and adjusted gross profits. Additionally, the company experienced increased operating expenses, primarily due to cost optimization efforts and severance expenses related to restructuring programs.", "ground_truth": "C.H. Robinson's financial performance in 2023 was primarily affected by weak freight demand and excess carrier capacity leading to reduced net income and operating cash flow, alongside declines in transportation rates."}
{"type": "financial", "level": "comp", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "comp_parts": [3, 4], "question": "How did the revenue recognition policy related to in-transit shipments change from December 31, 2022, to December 31, 2023?", "prediction": "The amount of revenue recognized for contracts where the transit period was partially complete declined significantly at December 31, 2023, compared to December 31, 2022, driven by macroeconomic and industry factors impacting the cost of purchased transportation. \n\n($189.9 million at December 31, 2023, vs. $257.6 million at December 31, 2022)", "ground_truth": "The revenue for contracts where the transit period was partially complete declined from $257.6 million at December 31, 2022, to $189.9 million at December 31, 2023, due to macroeconomic and industry factors impacting transportation costs."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 5], "question": "What was the total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, and how does it compare to the unrecognized compensation cost related to non-vested stock-based compensation arrangements as of the same date?", "prediction": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million. As of December 31, 2023, there was approximately $354.8 million of expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements, which will be recognized over a weighted average period of 2.42 years.", "ground_truth": "The total stock-based compensation expense for Exact Sciences Corporation for the year ended December 31, 2023, was $231.3 million, while the expected total unrecognized compensation cost related to non-vested stock-based compensation arrangements was approximately $354.8 million."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [2, 4], "question": "How did the research and development expenses change from 2022 to 2023 compared to sales and marketing expenses, and what were the main reasons for these changes?", "prediction": "Research and development expenses increased by $32.5 million from $393.4 million in 2022 to $425.9 million in 2023, while sales and marketing expenses decreased by $118.9 million from $846.0 million in 2022 to $727.1 million in 2023. The increase in research and development expenses was primarily due to an increase in personnel expenses and facility and support services associated with ongoing clinical trials and research and development efforts. The decrease in sales and marketing expenses was primarily due to a decrease in direct marketing costs and professional fees, personnel expenses, and facility and support services, reflecting a realignment of the sales force and reduction of advertising spend.", "ground_truth": "Research and development expenses increased by $32.5 million due to higher personnel expenses and facility costs, while sales and marketing expenses decreased by $118.9 million primarily due to reduced marketing costs and a realignment of the sales force."}
{"type": "financial", "level": "comp", "file": "EXACT SCIENCES CORPORATION.txt", "comp_parts": [1, 3], "question": "How did Exact Sciences Corporationâ€™s cash and cash equivalents at the end of 2023 compare with their amount at the beginning of the year, and what was the cause of this change based on their cash flow activities?", "prediction": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million at the end of 2023. This increase was due to net cash provided by operating activities of $156.1 million, as well as net cash provided by financing activities of $159.8 million, partially offset by cash used for investing activities of $49.7 million.", "ground_truth": "Exact Sciences Corporation's cash and cash equivalents increased from $242.5 million at the beginning of 2023 to $605.4 million by the end of the year, driven by positive net cash provided by operating activities and an increase in net cash provided by financing activities, including proceeds from the issuance of convertible notes."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 1], "question": "How much did Esperion's net product sales increase from 2022 to 2023, and how much did their collaboration revenue increase within the same period?", "prediction": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, a $22.4 million increase. Their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023, an $18.4 million increase.", "ground_truth": "Esperion's net product sales increased from $55.9 million in 2022 to $78.3 million in 2023, while their collaboration revenue increased from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [1, 4], "question": "How did Esperion Therapeutics, Inc.'s net loss change from 2022 to 2023 and what were the factors contributing to this change?", "prediction": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, resulting in a $24.5 million reduction in net loss. This decrease was primarily driven by a $22.4 million increase in net product sales, an $18.4 million increase in collaboration revenue, and a $32.8 million decrease in research and development expenses, partially offset by increases in selling, general, and administrative expenses and interest expense.", "ground_truth": "Esperion Therapeutics, Inc.'s net loss decreased from $233.7 million in 2022 to $209.2 million in 2023, primarily due to increased net product sales and collaboration revenue, partially offset by increased selling, general, and administrative expenses."}
{"type": "financial", "level": "comp", "file": "Esperion Therapeutics Inc.txt", "comp_parts": [0, 2], "question": "What changes occurred in the net product sales of NEXLETOL and NEXLIZET from 2022 to 2023, and how did the collaboration revenue compare during the same period?", "prediction": "From 2022 to 2023, net product sales of NEXLETOL and NEXLIZET increased by $22.4 million, rising from $55.9 million to $78.3 million. Collaboration revenue also rose, increasing from $19.6 million to $38.0 million during the same period.", "ground_truth": "Net product sales of NEXLETOL and NEXLIZET increased from $55.9 million in 2022 to $78.3 million in 2023, while collaboration revenue also grew from $19.6 million in 2022 to $38.0 million in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [2, 5], "question": "What was the percentage change in the Company's total revenue from the Property & Casualty insurance vertical from 2021 to 2023, compared to the Health insurance vertical for the same period?", "prediction": "From 2021 to 2023, MediaAlpha's revenue from Property & Casualty insurance decreased by 60.6% (from $417.7 million to $164.2 million), whereas Health insurance revenue increased by 5.5% (from $176.5 million to $186.3 million).", "ground_truth": "The Company's total revenue from Property & Casualty insurance vertical decreased by 60.7% from $417,715,000 in 2021 to $164,234,000 in 2023, while the Health insurance vertical saw a 5.6% increase from $176,459,000 in 2021 to $186,275,000 in 2023."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [0, 5], "question": "How did the revenue from Open Marketplace transactions compare to Private Marketplace transactions in the year ended December 31, 2023?", "prediction": "In the year ended December 31, 2023, revenue from Open Marketplace transactions was $378.7 million (63.8% of total Transaction Value), whereas revenue from Private Marketplace transactions was $9.4 million (only 2.5% of Open Marketplace revenue and 1.6% of the $587.9 million in total Transaction Value, but private marketplace generated $214.7 million of transaction value).", "ground_truth": "In the year ended December 31, 2023, Open Marketplace transactions generated $378,730,000 in revenue, which was significantly higher than Private Marketplace transactions which generated $9,419,000."}
{"type": "financial", "level": "comp", "file": "MediaAlpha, Inc..txt", "comp_parts": [3, 4], "question": "How did the decrease in P&C insurance revenue contribute to the overall decline in total revenue for the year ended December 31, 2023 compared to 2022?", "prediction": "The decrease in P&C insurance revenue for the year ended December 31, 2023, compared to the year ended December 31, 2022, was due primarily to a decrease in customer acquisition spending by P&C carriers in response to lower than expected underwriting profitability.", "ground_truth": "The P&C insurance revenue decreased by $60.1 million in 2023, primarily due to reduced customer acquisition spending by P&C carriers, contributing significantly to the overall decline in total revenue by $70.9 million compared to 2022."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [2, 4], "question": "What are the potential effects of regulatory changes on Mind Medicine's EU operations concerning data exclusivity and medical device regulations?", "prediction": "Potential effects include reduced data exclusivity (from 8 to 6 years), changes in regulatory requirements for medical devices, and impacts on the company's ability to maintain competitive advantage and ensure compliance with evolving EU regulations.", "ground_truth": "Regulatory changes in the EU, such as the proposal to reduce data exclusivity from eight to six years and the MDR governing medical devices, could affect Mind Medicine's product development timelines and compliance requirements, impacting their ability to market products efficiently in the EU."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [3, 4], "question": "Between December 31, 2022, and December 31, 2023, how much of the equity securities registered under the shelf registration statement was issued by the company?", "prediction": "$40.2 million of equity securities were issued by the company, leaving $59.8 million available for future issuance under the shelf registration statement and $40.0 million reserved for sales under the at-the-market equity offering program.", "ground_truth": "Between December 31, 2022, and December 31, 2023, the company issued $0.2 million of equity securities, as the availability decreased from $100.0 million to $99.8 million."}
{"type": "financial", "level": "comp", "file": "Mind Medicine (MindMed) Inc..txt", "comp_parts": [1, 3], "question": "What are some potential consequences mentioned in the financial statements if the company fails to comply with controlled substance laws and regulations when developing its product candidates?", "prediction": "Potential consequences include fines, penalties, loss of registrations, and restrictions on the company's ability to develop and commercialize its product candidates, which could have a material adverse effect on the company's business, financial condition, and results of operations.", "ground_truth": "Failure to comply with controlled substance laws and regulations may result in increased costs, enforcement actions, regulatory scrutiny, potential litigation, and criminal prosecution, which could delay or prevent product development and commercialization."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [0, 2], "question": "What percentage of NVIDIA's total revenue for fiscal year 2024 was generated by a single customer within the Compute & Networking segment, and what challenges does this concentration pose?", "prediction": "One customer, Customer A, accounted for 13% of NVIDIA's total revenue for fiscal year 2024, which was attributed to the Compute & Networking segment. This concentration poses challenges, such as the risk of losing this major customer or a significant reduction in their orders, which could negatively impact NVIDIA's revenue.", "ground_truth": "Sales to one customer, Customer A, represented 13% of total revenue for fiscal year 2024, posing challenges like potential revenue impact from losing or being unable to sell to such major customers due to trade restrictions."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 5], "question": "What was the change in NVIDIA's net income from January 29, 2023, to January 28, 2024, and how does this compare to the change in revenue for the same period?", "prediction": "NVIDIA's net income increased from $4,368 million to $29,760 million, representing a 581% increase. Revenue increased from $26,974 million to $60,922 million, representing a 126% increase. The percentage increase in net income (581%) exceeded the percentage increase in revenue (126%).", "ground_truth": "NVIDIA's net income increased from $4.37 billion on January 29, 2023, to $29.76 billion on January 28, 2024, while revenue increased from $26.97 billion to $60.92 billion during the same period."}
{"type": "financial", "level": "comp", "file": "NVIDIA Corporation.txt", "comp_parts": [1, 2], "question": "What percentage of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment, and how does this demonstrate a risk presented in the Risk Factors?", "prediction": "13% of NVIDIA's revenue for fiscal year 2024 came from a single customer in the Compute & Networking segment. This concentration of revenue demonstrates the risk of dependence on a limited number of customers, as presented in the Risk Factors section, specifically under \"Risks Related to Demand, Supply and Manufacturing\" and \"Risks Related to Our Global Operating Business\", where it is stated that the company's revenue is concentrated among a few large customers, and the loss of any of these customers could harm NVIDIA's financial condition and results of operations.", "ground_truth": "In fiscal year 2024, 13% of NVIDIA's revenue came from a single customer in the Compute & Networking segment, illustrating the risk of revenue concentration from limited partners and distributors, as mentioned in the Risk Factors."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [1, 3], "question": "How did Paratek's financial position affect their ability to utilize net operating loss carryforwards after the merger, and what was the impact on regulatory operations?", "prediction": "Paratek's history of losses and the merger led to a change in ownership, impacting their ability to utilize net operating loss carryforwards. As a result, the company's valuation allowance was established to prevent the recognition of benefits from federal and state deferred tax assets. This limitation affected the company's ability to offset future taxable income and tax from net operating loss carryforwards, influencing regulatory operations.", "ground_truth": "Paratek's financial position was impacted by ownership changes from the merger that limited the use of net operating loss carryforwards, which could materially affect cash flow and operations as government regulations require cost compliance in various areas."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [3, 4], "question": "How did the full-year net product revenue change for Paratek Pharmaceuticals' NUZYRA from 2021 to 2022, and what was the impact on the company's net loss for the same period?", "prediction": "Paratek Pharmaceuticals' full-year net product revenue for NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, representing a 29.6% year-over-year growth. This revenue increase contributed to a net loss of $63.6 million in 2022, which is higher than the net loss of $59.1 million in 2021. However, the net loss increased by $4.5 million between the two years, despite the revenue growth.", "ground_truth": "The net product revenue for Paratek Pharmaceuticals' NUZYRA increased from $106.1 million in 2021 to $136.8 million in 2022, while the net loss increased from $59.1 million in 2021 to $63.6 million in 2022."}
{"type": "financial", "level": "comp", "file": "Paratek Pharmaceuticals Inc.txt", "comp_parts": [0, 2], "question": "What are the factors affecting the commercialization success of NUZYRA in the U.S. as mentioned in the financial statements?", "prediction": "According to the financial statements, factors affecting the commercialization success of NUZYRA in the U.S. include:\n\n1. A lengthy and difficult regulatory approval process\n2. The need for extensive and expensive clinical trials to demonstrate efficacy and safety\n3. Competition from other antibiotics in the market\n4. The requirement for investments in infrastructure, manufacturing, and distribution to support commercialization\n5. The need for a large and experienced commercial organization to promote and distribute the product\n6. The requirement for substantial funding and financial resources from public or private markets or government funding\n7. Dependence on third-party manufacturing partners\n8. Economic and political risks associated with international operations \n9. Achieving market acceptance among physicians, patients, the medical community, and third-party payors\n10. Maintaining compliance with applicable laws and regulations\n11. Managing the potential impact of the COVID-19 pandemic and other external factors on commercialization efforts.", "ground_truth": "The success of NUZYRA's commercialization in the U.S. depends on securing starting materials, maintaining manufacturing arrangements, producing sufficient quantities, building sales and marketing capabilities, gaining product acceptance, obtaining sufficient reimbursement, and maintaining compliance with FDA requirements as mentioned in the financial statements."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 2], "question": "What were the factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023?", "prediction": "The factors contributing to the change in automotive sales revenue and gross margin from 2022 to 2023 included a lower average selling price on vehicles due to overall price reductions year over year, sales mix, a negative impact from the strengthening of the United States dollar against other foreign currencies, and a decrease in material costs and manufacturing costs from better fixed cost absorption. Additionally, a release of valuation allowance associated with the U.S. federal and certain state deferred tax assets resulted in a benefit in the provision for income taxes.", "ground_truth": "Automotive sales revenue increased by $11.30 billion due to a rise in Model 3 and Model Y deliveries, while the gross margin decreased from 28.5% to 19.4% due to lower average selling prices and increased costs."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [3, 5], "question": "How did Tesla's short-term investments and inventory change from December 31, 2022, to December 31, 2023?", "prediction": "Tesla's short-term investments increased from $5.932 billion to $12.696 billion from December 31, 2022, to December 31, 2023. The company's inventory also increased from $12.839 billion to $13.626 billion during the same period.", "ground_truth": "Tesla's short-term investments increased from $5,932 million in 2022 to $12,696 million in 2023, while inventory increased from $12,839 million in 2022 to $13,626 million in 2023."}
{"type": "financial", "level": "comp", "file": "Tesla, Inc..txt", "comp_parts": [1, 5], "question": "How do the commitments for capital expenditure and tax revenues in the state of New York compare to those in Shanghai, China for Tesla as of December 31, 2023?", "prediction": "As of December 31, 2023, Tesla had commitments for capital expenditure and tax revenues in the state of New York, where it operates Gigafactory New York, and in Shanghai, China, where it operates Gigafactory Shanghai. \n\nIn New York, Tesla is obligated to spend or incur $5.00 billion in combined capital, operational expenses, costs of goods sold, and other costs during the 10-year period beginning April 30, 2018. The company must also meet employment targets and specified minimum numbers of personnel in the State of New York and in Buffalo, New York.\n\nIn Shanghai, China, Tesla is required to spend RMB 14.08 billion in capital expenditures by the end of 2023, which was achieved, and generate RMB 2.23 billion of annual tax revenues starting at the end of 2023. \n\nTherefore, the commitments for capital expenditure in Shanghai are specific to a certain currency (RMB) and amount, whereas the commitments in New York are in USD and based on a combination of capital, operational expenses, costs of goods sold, and other costs. The tax revenue commitments also differ, with Shanghai requiring a specific annual tax revenue and New York having a 10-year period for meeting the tax revenue requirements.", "ground_truth": "As of December 31, 2023, Tesla committed to $5 billion in combined expenditures and costs in New York state by the end of 2029, while in Shanghai, China, Tesla committed to RMB 14.08 billion in capital expenditures and RMB 2.23 billion in annual tax revenues by the end of 2023, both of which have been achieved."}
